LOUISIANA reports a surge in severe Vibrio vulnificus infection cases, as early preclinical research explores novel experimental treatment options. Standard clinical protocols for managing fulminant Vibrio vulnificus infection rely on established regimens, including fluoroquinolones like ciprofloxacin or third generation cephalosporins. For now, clinicians managing Vibrio vulnificus infection must continue following established guidelines centered on swift antibiotic administration and timely surgical debridement. Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus infection. Vibrio vulnificus: 2026 Data and Guidance.